Integra LifeSciences Holdings Corporation (NASDAQ:IART – Get Free Report)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $18.30 and last traded at $17.61, with a volume of 2322863 shares traded. The stock had previously closed at $17.58.
Analyst Upgrades and Downgrades
IART has been the topic of several research analyst reports. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Thursday. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and increased their price target for the stock from $11.00 to $16.00 in a research report on Thursday, May 28th. Truist Financial decreased their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. Wells Fargo & Company lifted their price target on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $16.20.
Integra LifeSciences Stock Up 0.5%
Integra LifeSciences (NASDAQ:IART – Get Free Report) last issued its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same quarter last year, the firm earned $0.41 EPS. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.
Hedge Funds Weigh In On Integra LifeSciences
Large investors have recently modified their holdings of the stock. Rubric Capital Management LP increased its stake in Integra LifeSciences by 58.4% during the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock worth $90,233,000 after acquiring an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY grew its holdings in shares of Integra LifeSciences by 50.6% during the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after purchasing an additional 1,347,700 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares during the last quarter. Invenomic Capital Management LP increased its position in Integra LifeSciences by 78.3% during the 4th quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock valued at $13,115,000 after purchasing an additional 463,729 shares during the period. Finally, Kotler Kevin bought a new position in shares of Integra LifeSciences in the 4th quarter worth about $5,309,000. 84.78% of the stock is owned by institutional investors.
Integra LifeSciences Company Profile
Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.
Featured Articles
- Five stocks we like better than Integra LifeSciences
- Why Penguin Solutions Is Rallying as AI Data Centers Scale
- SpaceX’s Historic IPO Has Already Sparked a 2X ETF Frenzy
- Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE?
- Royal Caribbean’s Best Quarter Ever Still Leaves a Big Question
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
